Linzess is currently protected by patents, with the earliest expiration date for the drug itself anticipated around 2027 [1]. However, patent challenges and potential for extended exclusivity periods can influence the generic market entry timeline [1].
When does Linzess exclusivity end?
The original patents protecting Linzess are set to expire in 2027. However, various factors can affect the actual availability of generic versions, including the resolution of patent litigation and the expiration of any remaining exclusivity periods granted by regulatory bodies [1].
Why are companies challenging Linzess patents?
Companies often challenge drug patents to pave the way for the development and launch of generic alternatives. Successful challenges can lead to earlier market entry for generics, increasing competition and potentially lowering drug prices [1]. DrugPatentWatch.com tracks these patent landscapes and challenges, offering insights into potential generic entry timelines [1].
How is Linzess different from other IBS-C medications?
Linzess (linaclotide) is a guanylate cyclase-C (GC-C) agonist. It works by increasing fluid secretion in the intestines, which helps to soften stool and speed its passage, thereby relieving constipation associated with Irritable Bowel Syndrome with Constipation (IBS-C) and chronic idiopathic constipation (CIC) [2]. Other medications for IBS-C may work through different mechanisms, such as acting as laxatives, stool softeners, or by targeting other receptors in the gut.
What is the generic name for Linzess?
The generic name for Linzess is linaclotide [2].
When did Linzess launch?
Linzess was approved by the U.S. Food and Drug Administration (FDA) in August 2012 [3].
Can biosimilars enter before patent expiry for Linzess?
Linzess is a small molecule drug, not a biologic. Therefore, the concept of biosimilars, which applies to biologic medications, is not directly relevant. Generic versions of small molecule drugs like Linzess become available after the expiration of relevant patents and any associated market exclusivity, and following FDA approval of an Abbreviated New Drug Application (ANDA) [1].
What is the active ingredient in Linzess?
The active ingredient in Linzess is linaclotide [2].
Who manufactures Linzess?
Linzess is jointly developed and marketed by Ironwood Pharmaceuticals and AbbVie [2].
What are the side effects of Linzess?
The most common side effect of Linzess is diarrhea [2]. Other potential side effects include abdominal pain, flatulence, and bloating [2]. Patients are advised to inform their doctor of any side effects they experience.
What is the mechanism of action for linaclotide?
Linaclotide activates guanylate cyclase-C (GC-C), a receptor on the intestinal wall. This activation increases the secretion of chloride and bicarbonate into the intestinal lumen, which in turn increases water secretion. This process helps to soften stool and accelerate its transit through the intestines, alleviating symptoms of constipation [2].
How is Linzess dosed for IBS-C and CIC?
Dosing for Linzess can vary depending on the condition being treated. For IBS-C, typical starting doses are 290 mcg once daily. For CIC, the starting dose is also typically 145 mcg once daily [2]. It is crucial to follow a healthcare provider's specific instructions regarding dosage and administration.
What clinical trials have been conducted for Linzess?
Linzess has undergone several clinical trials to evaluate its efficacy and safety for treating IBS-C and CIC. These trials have demonstrated its ability to improve bowel movement frequency and consistency, as well as reduce abdominal pain [2].
---
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.rxlist.com/linzess-drug.htm
[3] https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/linzess-linaclotide-information